Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.

Musso CG, Belloso WH, Glassock RJ.

World J Nephrol. 2016 Jan 6;5(1):33-42. doi: 10.5527/wjn.v5.i1.33. Review.

2.

Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database.

Kalemeera F, Mengistu AT, Gaeseb J.

J Pharm Policy Pract. 2015 Apr 20;8(1):14. doi: 10.1186/s40545-015-0034-6. eCollection 2015.

3.

Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.

Mamiafo CT, Moor VJ, Nansseu JR, Pieme CA, Tayou C, Yonkeu JN.

AIDS Res Ther. 2014 Jan 15;11(1):2. doi: 10.1186/1742-6405-11-2.

4.

A review of the toxicity of HIV medications.

Margolis AM, Heverling H, Pham PA, Stolbach A.

J Med Toxicol. 2014 Mar;10(1):26-39. doi: 10.1007/s13181-013-0325-8. Review.

5.

Metabolic complications and treatment of perinatally HIV-infected children and adolescents.

Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM.

J Int AIDS Soc. 2013 Jun 18;16:18600. doi: 10.7448/IAS.16.1.18600. Review.

6.

Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.

Thorsteinsson K, Ladelund S, Jensen-Fangel S, Johansen IS, Katzenstein TL, Pedersen G, Storgaard M, Obel N, Lebech AM.

BMC Infect Dis. 2012 Nov 12;12:293. doi: 10.1186/1471-2334-12-293.

7.

Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In Botswana.

Moyo S, Bussmann H, Mangwendeza P, Dusara P, Gaolathe T, Mine M, Musonda R, van Widenfelt E, Novitsky V, Makhema J, Marlink RG, Essex M, Wester CW.

J Antivir Antiretrovir. 2011 Oct;3(4):45-48. Epub 2011 Sep 20.

8.

Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial.

Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):759-65. doi: 10.1089/AID.2011.0303. Epub 2012 Jun 1.

9.

Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, Knecht G, Sarrazin C, Friedrich-Rust M, Forestier N, Poynard T, Zeuzem S, Herrmann E, Hofmann WP.

BMC Gastroenterol. 2012 Mar 27;12:27. doi: 10.1186/1471-230X-12-27.

10.

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Gutierrez AD, Balasubramanyam A.

Endocrine. 2012 Feb;41(1):1-10. doi: 10.1007/s12020-011-9565-z. Epub 2011 Dec 2. Review.

11.

Liver disease, HIV and aging.

Falade-Nwulia O, Thio CL.

Sex Health. 2011 Dec;8(4):512-20. doi: 10.1071/SH10163. Review.

12.

Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications.

Crain MJ, Williams PL, Griner R, Tassiopoulos K, Read JS, Mofenson LM, Rich KC; Pediatric HIVAIDS Cohort Study.

Pediatr Infect Dis J. 2011 Dec;30(12):1069-74. doi: 10.1097/INF.0b013e318234c886.

13.

A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy.

Matthews LT, Giddy J, Ghebremichael M, Hampton J, Guarino AJ, Ewusi A, Carver E, Axten K, Geary MC, Gandhi RT, Bangsberg DR.

PLoS One. 2011 Apr 11;6(4):e18736. doi: 10.1371/journal.pone.0018736.

15.

The role of toxicity-related regimen changes in the development of antiretroviral resistance.

Nevin CR, Ye J, Aban I, Mugavero MJ, Jackson D, Lin HY, Allison J, Raper JL, Saag MS, Willig JH.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):957-63. doi: 10.1089/AID.2010.0291. Epub 2011 Mar 21.

16.

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.

J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.

Supplemental Content

Support Center